Altamira Therapeutics

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray https://lnkd.in/e8JeTFDC

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results https://lnkd.in/eZcaiyTp

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 https://lnkd.in/ejYtxutp

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering https://lnkd.in/e-wmaZPN

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering https://lnkd.in/ema_Ww7X

📅 Join us for the next edition of our Pitch & Connect, featuring Altamira Therapeutics and Midas Pharma! Get ready for an inspiring session of presentations followed by a networking lunch at our Main Campus HQ. Meet the innovators: ✔ Dr. Covadonga Paneda, COO of Altamira Therapeutics Altamira is pioneering RNA-based therapeutics for cancer and inflammatory diseases. Having relocated its R&D lab to Switzerland Innovation Park Basel Area, the team is advancing treatments using their proprietary OligoPhore™ / SemaPhore™ delivery platform. ✔ Sigrid Saaler-Reinhardt, Prof. Dr., Head of Innovation at Midas Pharma Midas Pharma is dedicated to biotech innovation, providing regulatory and GMP manufacturing services. Their focus at Switzerland Innovation Park Basel Area is tackling the challenges of biomolecule delivery. Event details: Date: Thursday, 19 September 2024 Time:12:00 –13:15 Location: Switzerland Innovation Park Basel Area - Main Campus, Aula Hegenheimermattweg 167A, 4123 Allschwil 👉 Register today: https://lnkd.in/ejKMawbY Let’s connect, learn, and grow together. Karin Crisanto | Franziska Dornblut | Carine Moya | Tebbe de Vries #Innovation #Biotech #Healthcare #RNA #MainCampus

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia https://lnkd.in/eRPejzNp

Welcome to our Switzerland Innovation Park Basel Area - Main Campus! 🚀 Altamira Therapeutics is dedicated to unlocking the potential of RNA delivery beyond the liver using its proprietary delivery platform OligoPhore™ / SemaPhore™. The platform is used in Altamira’s flagship programs, AM-401, for the treatment of KRAS driven cancer, and AM-411, for the treatment of rheumatoid arthritis, as well as by partners for extrahepatic delivery and strong endosomal release of their proprietary RNA molecules. 💬 We asked Altamira what they are looking forward to achieving at their new location: "Our immediate goal is to boost our RNA delivery platform as well our pipeline in the areas of oncology and inflammatory disease. Access to a laboratory ensures that we can diversify our technology and expand our intellectual property. Moreover, integration within the Switzerland Innovation Park Basel Area's vibrant community should also give our team the opportunity to grow scientifically and establish long-standing connections that we are sure will contribute to the company’s success," said the team.  We’re delighted to have you with us Nicole Grosse, Veronica Verona Francardo, Céline Potot Viarouge, Covadonga Paneda & team! 🤝 👉Meet our residents over here:https://lnkd.in/evNfS8hA Franziska Dornblut | Carine Moya | Karin Crisanto #innovation #startups #RNA #biotech #Therapeutics

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 bit.ly/3MvCY1z

Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) https://lnkd.in/eQQxvhUN